Physician profile
Mircea M Basaraba
NPI 1316974637
$78,286.79
in general payments reported to CMS, 2019-2025
38 companies · $14K in 2025
The $14K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,387 · 2020: $5,279 · 2021: $4,678 · 2022: $5,674 · 2023: $14K · 2024: $32K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $59K · Food and Beverage: $2,318 · Travel and Lodging: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $58,716.67 |
| Food and Beverage | $2,318.46 |
| Travel and Lodging | $233.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $68,301.56 | 2019-2025 | Auryon Laser System 100-120 Vac, Venacure 1470 Pro, Auryon Laser System 100-120 Vac |
| Penumbra, INC. | $1,330.30 | 2022 | |
| Cardiovascular Systems INC. | $1,227.58 | 2019-2023 | Diamondback Peripheral |
| Medtronic, INC. | $1,210.69 | 2021-2024 | Linq II |
| Boston Scientific Corporation | $959.45 | 2019-2025 | Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $925.65 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $840.68 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $668.47 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $552.88 | 2021-2024 | Venclose Maven Catheter, Venovo |
| Sanofi-Aventis U.S. LLC | $281.66 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $266.64 | 2021-2025 | Verquvo, Capvaxive |
| Abiomed | $198.71 | 2022-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.63 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $139.36 | 2020-2025 | Farxiga, Wainua |
| Abbott Laboratories | $122.90 | 2021-2024 | Jeti All In One Non-Sterile Kit |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $116.67 | 2021 | |
| Philips North America LLC | $108.31 | 2022 | |
| Pfizer INC. | $103.89 | 2023-2025 | |
| Edwards Lifesciences Corporation | $87.71 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| E.R. Squibb & Sons, L.L.C. | $78.37 | 2019-2025 | Camzyos |
| Genzyme Corporation | $62.64 | 2023 | |
| Amgen INC. | $62.15 | 2021-2025 | Repatha, Repatha |
| Novo Nordisk INC | $57.37 | 2023-2025 | Ozempic, Rybelsus |
| Medtronic Vascular, INC. | $50.61 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.45 | 2025 | |
| Shockwave Medical, INC | $46.00 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Baxter Healthcare | $37.54 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Venclose INC. | $35.31 | 2020 | |
| Reflow Medical INC | $28.31 | 2025 | |
| Bardy Diagnostics, INC. | $28.00 | 2020 | |
| Impulse Dynamics (USA) INC. | $27.65 | 2021 | |
| Qorumpartners | $24.11 | 2022 | |
| Coala Life INC | $22.69 | 2022 | |
| Stryker Corporation | $19.06 | 2025 | Clottriever Bold Catheter |
| Recor Medical INC | $18.33 | 2025 | Paradise Ultrasound Renal Denervation System |
| Biocompatibles, INC. | $17.99 | 2019 | |
| Cordis US Corp. | $17.81 | 2025 | Mynx Control Venous |
| Lundbeck LLC | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mircea Basaraba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.